Dengue vaccine results prompt both disappointment and hope

The first vaccine against dengue fever to reach large-scale trials has produced mixed results in a phase II study.

Dengue fever is spread by several species of mosquito, including the Asian tiger mosquito | SCIENCE PHOTO LIBRARY
Dengue fever is spread by several species of mosquito, including the Asian tiger mosquito | SCIENCE PHOTO LIBRARY

Researchers expressed surprise over the lower than expected efficacy of the vaccine, but nevertheless hailed the demonstration that a vaccine against dengue fever is possible as a 'breakthrough'.

Dengue fever is a mosquito-borne viral disease for which there is currently no specific treatment or vaccine. Consequently, cases are managed with supportive measures. Approximately half the world's population lives in countries where dengue fever is endemic.

In the phase II study, 4,002 Thai children aged 4 to 11 years were randomised to receive either the experimental dengue vaccine or control (rabies vaccine or placebo) at 0, 6 and 12 months. 

Overall vaccine efficacy in the per-protocol analysis (n=3,673) was 30.2%, with statistically significant efficacy reported for dengue virus serotypes (DENV) 1, 3 and 4 after at least one injection (61.2%, 81.9% and 90%, respectively) but not after three injections. However, efficacy against DENV2, which accounted for 59% of episodes, was not shown.

Dengue vaccine was well tolerated, with no reported vaccine-related serious adverse events or other safety signals after two years of active follow-up.

The vaccine, developed by Sanofi Pasteur MSD and known as CYD-TDV, is a recombinant, live attenuated, tetravalent vaccine based on the yellow fever 17D vaccine strain.

Two randomised controlled phase III trials of the vaccine involving more than 30,000 children are currently underway in Asia and Latin America. They are designed to assess its efficacy in preventing symptomatic virologically confirmed dengue cases, regardless of severity or serotype.

The Asian trial is recruiting children aged 2 to 14 years and is expected to complete in July 2014. The Latin American trial has enrolled children aged 9 to 16 years and has an anticipated finish date of August 2016.

Travel health factsheet on dengue fever

Follow MIMS on Twitter


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases